Online citations, reference lists, and bibliographies.
← Back to Search

Enfermedades Pleurales Malignas

J. M. Juan, B. R. Romero
Published 2010 · Medicine, Chemistry

Cite This
Download PDF
Analyze on Scholarcy
Share
This paper references
10.1183/09031936.97.10071648
Pleurodesis: state of the art.
F. Rodríguez-Panadero (1997)
10.1016/S0140-6736(07)60708-9
Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study
J. Janssen (2007)
10.1158/1078-0432.CCR-06-2144
Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment
B. Grigoriu (2007)
10.1016/S0140-6736(07)60412-7
Ecological association between asbestos-related diseases and historical asbestos consumption: an international analysis
Ro-Ting Lin (2007)
10.1157/13071586
Normativa sobre el asbesto y sus enfermedades pleuropulmonares (Grupo de Trabajo EROL-SEPAR)
K. Shams (2005)
10.1159/000113629
Pathophysiology of the Pleura
M. Jantz (2008)
10.1002/14651858.CD002916.PUB2
Pleurodesis for malignant pleural effusions.
P. Shaw (2004)
10.1183/09031936.98.12040972
Malignant pleural mesothelioma.
C. Boutin (1998)
10.1093/OXFORDJOURNALS.AJE.A009616
Pleural mesothelioma: dose-response relation at low levels of asbestos exposure in a French population-based case-control study.
Y. Iwatsubo (1998)
10.1201/B14205-28
Malignant pleural effusions.
S. Sahn (1985)
10.1111/j.1440-1843.2004.00566.x
Management of malignant pleural effusions
Y. Lee (2004)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
Pleural metastatic tumours and effusions. Frequency and pathogenic mechanisms in a post-mortem series.
F. Rodríguez-Panadero (1989)
10.1016/S0022-5223(19)37535-X
Adult respiratory distress syndrome following intrapleural instillation of talc.
J. Rinaldo (1983)
10.1136/thx.31.1.15
Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients.
E. Butchart (1976)
Thoracoscopy: present diagnostic and therapeutic indications.
R. Loddenkemper (1993)
10.1016/S1579-2129(06)60416-3
[Guidelines on asbestos-related pleuropulmonary disease].
I. Isidro Montes (2005)
10.1200/JCO.20005.14.589
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
10.1016/S0003-4975(96)00808-9
Thoracoscopic talc insufflation versus talc slurry for symptomatic malignant pleural effusion.
A. Yim (1996)
10.1159/000029239
Are Prognostic Factors Helpful in Determining the Indication for Pleurodesis in Malignant Pleural Effusions?
R. Loddenkemper (1998)
10.1378/CHEST.117.1.87
Pleural fluid pH as a predictor of pleurodesis failure: analysis of primary data.
J. Heffner (2000)
10.1016/S0003-4975(99)01482-4
Outpatient management of malignant pleural effusion by a chronic indwelling pleural catheter.
J. Putnam (2000)
10.1183/09031936.00063109
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
A. Scherpereel (2009)
10.1002/1097-0142(19860115)57:2<324::AID-CNCR2820570222>3.0.CO;2-Y
Pleural effusion in breast cancer. Thoracoscopy for hormone receptor determination
M. Levine (1986)
10.1378/CHEST.122.3.1018
Influence of particle size on extrapleural talc dissemination after talc slurry pleurodesis.
J. Ferrer (2002)
10.1164/rccm.200802-258OC
Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study.
E. Park (2008)
10.1200/JCO.2008.20.3943
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
L. Krug (2009)
Latent period for malignant mesothelioma of occupational origin.
B. Lanphear (1992)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1097/JTO.0b013e318189f53d
Diagnostic and Prognostic Implications of Pleural Adhesions in Malignant Effusions
S. Bielsa (2008)
10.1183/09031936.98.11010213
Thoracoscopy--state of the art.
R. Loddenkemper (1998)
10.1378/CHEST.128.3.1431
Clinical efficacy and safety of thoracoscopic talc pleurodesis in malignant pleural effusions.
S. Kolschmann (2005)
10.1510/icvts.2009.213611
Staging algorithm for diffuse malignant pleural mesothelioma.
M. Zieliński (2010)
10.1378/CHEST.108.4.1122
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.
V. Rusch (1995)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar